• 1.

    Brener Z., 1979. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the western hemisphere. Pharmacol. Therapeut., 7 :7190.

    • Search Google Scholar
    • Export Citation
  • 2.

    Gutteridge W. E., 1981. Chemotherapy of Chagas' disease. Pages 4757 inBaker J. R., eds., Perspectives in Trypanosomiasis Research., Proc. 21st Trypanosomiasis Seminar, London. Research Studies Press, Chichester.

    • Search Google Scholar
    • Export Citation
  • 3.

    Duncan B. 1982. American trypanosomiasis (Chagas' disease). Pages 14371445 inWedgwood R. J., Davis S.D., Ray C. G., Kelley V. C., eds., Infections in Children, Harper and Row, Philadelphia.

    • Search Google Scholar
    • Export Citation
  • 4.

    McCabe R. E., Araujo F. S., Remington J. S., 1983. Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. Am. J. Trap. Med. Hyg., 32 :960962.

    • Search Google Scholar
    • Export Citation
  • 5.

    McCabe R. E., Remington J. S., Araujo F. S., 1984. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J. Infect. Dis., 150 :594601.

    • Search Google Scholar
    • Export Citation
  • 6.

    Sanderson C.J., Thomas J. A., Twomey C. E., 1980. The growth of Trypanosoma cruzi in human diploid cells for the production of trypomastigotes. Parasitology, 80 :153162.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ribeiro L. V., Kimura E., Fernandes J. F., 1969. Factors affecting the density of intracellular infection of tissue culture cells by Trypanosoma cruzi. Rev. Brasil. Bioi., 29 :295308.

    • Search Google Scholar
    • Export Citation
  • 8.

    Finney D. J., 1964. Probit Analysis, Second edition. Cambridge University Press, London.

  • 9.

    Wilson H. R., Ptacek B., 1974. Use of the C3H mouse in experimental chemotherapy of Chagas' disease. Third Inti. Congr. Parasitol. Proc., 3 :12931294.

    • Search Google Scholar
    • Export Citation
  • 10.

    Wilson H. R., Revankar G. R., Tolman R. L., 1974. In vitro and in vivo activity of certain thiosemicarbazones against Trypanosoma cruzi. J. Med. Chem., 17 :760761.

    • Search Google Scholar
    • Export Citation
  • 11.

    Maxwell A. E. 1961. Analyzing Quantitative Data. Spottiswoode, Ballantyne and Co., Ltd., London. 1323.

  • 12.

    Brener Z., Chiari E., 1971. The effects of some immunosuppressive agents in experimental Chagas' disease. Trans. R. Soc. Trap. Med. Hyg., 65 :629636.

    • Search Google Scholar
    • Export Citation
  • 13.

    Martinez-Silva R., Lopez V. A., Colon J. I., Chiriboga J., 1969. Isolation of Trypanosoma cruzi from blood of acutely and chronically infected mice in tissue culture. Am. J. Trop. Med. Hyg., 18 :878884.

    • Search Google Scholar
    • Export Citation
  • 14.

    Murray P. K., Habbersett M. C., Meurer R. D., 1983. Trypanosoma cruzi: Efficacy of the 2-substituted, 5-nitroimidazoles, MK-436 and L634, 549, in tissue culture and mice. Am. J. Trop. Med. Hyg., 32 :12421250.

    • Search Google Scholar
    • Export Citation
  • 15.

    Raether W., Seidenath H., 1984. Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei, and Entamoeba histolylica in vivo. Z. Parasitemia, 70 :135138.

    • Search Google Scholar
    • Export Citation

 

 

 

 

The Efficacy of an N-Substituted Imidazole, RS-49676, Against a Trypanosoma Cruzi Infection in Mice

View More View Less
  • Department of Antimicrobial Chemotherapy, Institute of Animal Science, Syntex Research, Palo Alto, California 94303

In vitro studies against epimastigotes and intracellular amastigotes and in vivo studies in inbred C3H/He mice infected with Trypanosoma cruzi Brazil strain were performed to determine the activities of two N-substituted imidazole compounds, RS- 49676 and ketoconazole. Both compounds are extremely active in vitro against the amastigotes (ED50 <0.0001 μg/ml) yet inactive against the epimastigotes. In vivo, RS-49676 increased the mean survival time over 11 weeks beyond the untreated control when given subcutaneously twice daily at 100 mg/kg/day. Ketoconazole increased the mean survival time 11-18 days beyond the untreated control (mean survival time 22 days) when given subcutaneously twice daily at 100 mg/kg or orally once daily at 100 mg/kg. Approximately 20%-25% of the RS-49676 treated mice were cured as determined by culturing the blood of infected mice with fibroblast lung cells. None of the ketoconazole mice were cured.

Save